Managing Partner

11/2022 – offen

The Challenge:

Due diligence for investors of life sciences early-stage startups

The How and Why:

Performed comprehensive organizational design evaluations, conducted strategic and disruption potential analyses, and developed tailored consulting approaches to client needs. Supported clients in risk assessment, market validation, and competitive landscape analysis. Provided guidance on go-to-market strategies and team assessments.

Outcome:

Enhanced decision-making frameworks for clients, enabling successful investment strategies, and innovation adoption.

Innovationsberater

4/2019 – 3/2022

The Challenge:

Driving agile transformation across the organization to improve efficiency and interdependency management. Transformation focus German pharma affiliate with 1500 employees.

The How and Why:

Served as a corporate-wide coach for executives, conducting leadership coaching and stakeholder alignment workshops. Trained SCRUM Masters and Product Owners in agile methodology and implemented ‘Flight Level Kanban’ to optimize study management in German affiliate. Acted as SCRUM Master for the global ‘STEP’ reorganization initiative at senior executive level. Supported cross-functional collaboration and introduced strategic roadmaps for efficiency improvements. Facilitated project prioritization and process optimization workshops in Germany, Africa, and Latin America.

Outcome:

Introduced OKRs (Objectives and Key Results) in the German Pharma affiliate, reduced investor-initiated study initiation timelines from 24 to 6 months, and improved cross-functional collaboration, supporting largescale organizational transformation.

Change Management, Transformation Management

4/2017 – 3/2019

The Challenge:

Launching Hemlibra® (Emicizumab) for hemophilia patients in Germany amidst regulatory and market pressures, and managing Esbriet® (Pirfenidon) in a mature lifecycle stage.

The How and Why:

Managed a team of 9 employees (office and field-based) and introduced SCRUM methodology in Medical Affairs. Coached teams in crossfunctional settings, supported key opinion leader engagement, and aligned clinical trials with commercialization efforts. Led medical strategy development, ensuring compliance with regulatory affairs and postmarket surveillance requirements. Conducted sales training and prepared teams for customer onboarding.

Outcome:

Launched successfully Hemlibra® in major hemophilia centers in Germany, achieving improved patient outcomes. Attained 100% satisfaction in Roche employee surveys and received an award for SCRUM implementation in Medical Affairs.

Director of Medical Affairs

2/2016 – 3/2017

The Challenge:

Launching Cresemba® (Isavuconazole) and Zevtera® (Ceftobiprole) in a competitive, cost-sensitive, and regulated Swiss market while ensuring access for compassionate use programs.

The How and Why:

3/4

Developed and executed strategic go-to-market strategies for Switzerland. Conducted salesforce training on medical education and product knowledge, supported thought leader engagement, and aligned clinical research with commercialization goals. Provided operational support for compassionate use initiatives and ensured compliance with regulatory standards.

Outcome:

Achieved successful market entry for both products, ensuring regulatory compliance and patient access.

Medical Affairs Manager

4/2014 – 1/2016

The Challenge:

Advising on health policy and market access challenges related to Germany’s market access landscape (GBA & IQWiG), ensuring alignment with corporate objectives.

The How and Why:

Provided strategic public health advice to the Berlin Office Manager, developed market access strategies, and conducted stakeholder engagement workshops to navigate regulatory barriers. Trained internal teams on AMNOG frameworks and supported the creation of the Lixiana® (Edoxaban) AMNOG dossier. Conducted competitive intelligence and prepared teams for AMNOG hearing.

Outcome:

Enhanced company positioning within Germany’s health policy environment, improving strategic corporate alignment. Secured a “minor additional benefit” label for Lixiana® in the AMNOG process.

Market Access

8/2012 – 3/2014

The Challenge:

Alliance management with Eli Lilly and The Medicines Company, as well as initiating and negotiating a co-promotion pilot with Vifor Germany. Navigating complex negotiations to prevent reference price grouping for Efient® (Prasugrel).

The How and Why:

Conducted strategic evidence-based medicine analyses and developed a concept to stop the reference price group process for Efient®, leveraging real-world evidence data. Facilitated alliance alignment workshops, structured contract negotiations, and built strategic partnerships to strengthen business ties. Trained internal teams on AMNOG policies and designed strategies for market expansion.

Outcome:

Successfully stopped the reference price group process Efient®, safeguarding its market position and preventing negative impacts on its international price landscape. Strengthened partnerships with Eli Lilly, The Medicines Company, and Vifor.

Business Development

4/2010 – 7/2012

The Challenge:

Managing regional medical projects and navigating complex payor stakeholder dynamics in South Germany and Switzerland.

The How and Why:

4/4

Daiichi Sankyo Germany

Location: Berlin, Germany Period : 04/2010 – 07/2012

Provided internal consulting on pricing and reimbursement strategies within the AMNOG framework. Conducted salesforce training on pricing policies and market access. Managed key opinion leader engagement, aligned clinical research with commercialization efforts, and organized advisory boards and scientific symposia to address payor concerns. Improved cross-functional collaboration between medical and commercial teams through workshops. Wrote AMNOG dossier for Sevikar®HCT.

Outcome:

Strengthened relationships with payors, improved regional medical project outcomes, and enhanced corporate positioning in key markets.

Medical Affairs Manager, Market Access

4/2008 – 3/2010

The Challenge:

Launching Sevikar® (Olmesartan/Amlodipine) in Switzerland and managing the Swiss launch of Efient® (Prasugrel) amidst competitive market conditions in alliance with Eli Lilly Switzerland.

The How and Why:

Developed and executed the go-to-market strategy for Sevikar® with a team of 20 sales representatives. Conducted salesforce training on product knowledge and compliance, organized advisory boards, and aligned clinical trials with commercialization efforts. Acted as the Pharmacovigilance responsible for Switzerland. Wrote BAG Swiss value dossier for Sevikar® .

Outcome:

Achieved best-in-class global launch results for Efient® in 2010 and positioned Sevikar® as a treatment option in the Swiss market.

Marketing Manager, Medical Affairs Manager

3/2006 – 3/2008

The Challenge:

Managing medical affairs for mature cardiovascular and antidiabetic drugs in a highly competitive therapeutic area.

The How and Why:

Developed medical strategies to support product positioning, conducted key opinion leader engagement, and ensured compliance. Led scientific communication efforts, facilitated salesforce training on clinical messaging, and supported real-world evidence generation to sustain competitive differentiation.

Outcome:

Strengthened the market positioning of key products, contributing to revenue loss reduction due to generics market entry.

Medical Affairs Manager